9.27
Absci Corp stock is traded at $9.27, with a volume of 8.66M.
It is up +15.30% in the last 24 hours and up +0.32% over the past month.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
See More
Previous Close:
$8.04
Open:
$8.295
24h Volume:
8.66M
Relative Volume:
1.91
Market Cap:
$1.59B
Revenue:
$1.84M
Net Income/Loss:
$-118.44M
P/E Ratio:
-11.18
EPS:
-0.8291
Net Cash Flow:
$-98.51M
1W Performance:
+12.50%
1M Performance:
+0.32%
6M Performance:
+205.94%
1Y Performance:
+263.53%
Absci Corp Stock (ABSI) Company Profile
Name
Absci Corp
Sector
Industry
Phone
(360) 949-1041
Address
18105 SE MILL PLAIN BLVD, VANCOUVER
Compare ABSI vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ABSI
Absci Corp
|
9.27 | 1.41B | 1.84M | -118.44M | -98.51M | -0.8291 |
|
VRTX
Vertex Pharmaceuticals Inc
|
516.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
789.45 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
|
MRNA
Moderna Inc
|
158.07 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
ARGX
Argen X Se Adr
|
995.77 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
196.94 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-02-25 | Initiated | JP Morgan | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jan-22-25 | Initiated | Needham | Buy |
| Oct-02-24 | Initiated | Guggenheim | Buy |
| Jul-03-24 | Initiated | Morgan Stanley | Overweight |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-04-23 | Initiated | H.C. Wainwright | Buy |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Jul-18-22 | Initiated | Truist | Buy |
| Mar-02-22 | Resumed | Cowen | Market Perform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Nov-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Aug-16-21 | Initiated | BofA Securities | Neutral |
| Aug-16-21 | Initiated | Cowen | Market Perform |
| Aug-16-21 | Initiated | Credit Suisse | Outperform |
| Aug-16-21 | Initiated | Stifel | Hold |
View All
Absci Corp Stock (ABSI) Latest News
Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as Ozempic - Yahoo Finance
Lifesci Capital Begins Coverage on Absci (NASDAQ:ABSI) - MarketBeat
ABSI Stock Eyes Best Day Ever After Positive Hair Loss Drug Data, $100M Lilly-Backed Raise - Stocktwits
Absci (ABSI) Institutional Ownership 2026 - MarketBeat
BTIG Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $16 - moomoo.com
Absci Corporation Stock (ABSI) Opinions on Investor Conference Participation - Quiver Quantitative
Bank of New York Mellon Corp Buys Shares of 386,832 Absci Corporation $ABSI - MarketBeat
ABSI: Absci Corp Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Absci Corporation $ABSI Shares Bought by Bank of America Corp DE - MarketBeat
Absci Corp (ABSI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Absci (NASDAQ:ABSI) Stock Price Down 4.8%Should You Sell? - MarketBeat
Can Absci’s (ABSI) Low-Frequency Hair Loss Therapy Redefine Its Long-Term Platform Potential? - simplywall.st
Absci Corp CFO Zachariah Jonasson Reports RSU Tax Withholding Share Transaction - Kalkine Media
Absci to Participate in Upcoming Investor Conferences - The Manila Times
Deutsche Bank AG Acquires New Stake in Absci Corporation $ABSI - MarketBeat
Artia Global Partners LP Acquires Shares of 464,444 Absci Corporation $ABSI - marketbeat.com
Absci (NASDAQ:ABSI) Trading 8.5% HigherWhat's Next? - MarketBeat
Certain Common Stock of Absci Corporation are subject to a Lock-Up Agreement Ending on 24-AUG-2026. - marketscreener.com
Absci (NASDAQ:ABSI) Shares Gap UpShould You Buy? - MarketBeat
Morgan Stanley Maintains Absci Corp(ABSI.US) With Hold Rating, Raises Target Price to $10 - 富途牛牛
Absci (ABSI) Q2 2026 Earnings Call Transcript - AOL.com
Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does. - GlobeNewswire
Ransi Mudalinayake Somaratne Net Worth (2026) - GuruFocus
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci - Zacks Investment Research
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma - The Globe and Mail
ABSI Looks 1092.2% Overvalued on GF Value™ - GuruFocus
Absci Corp (ABSI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Absci Corporation (NASDAQ:ABSI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Absci (NASDAQ:ABSI) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Absci (NASDAQ:ABSI) Trading Down 4.4%Here's Why - MarketBeat
Will Absci (NASDAQ:ABSI) Spend Its Cash Wisely? - Moomoo
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $11 - Moomoo
H.C. Wainwright Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Absci Corporation (ABSI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Absci Corp. Earnings Call Highlights ABS-201 And Cash - The Globe and Mail
A Quick Look at Today's Ratings for Absci Corp(ABSI.US), With a Forecast Between $11 to $16 - Moomoo
Absci (ABSI) On Early ABS 201 Data And Lilly Deal That Could Support Its Valuation - Yahoo Finance
Absci (ABSI) Could Be 32% Undervalued Following ABS 201 Data And Earnings - simplywall.st
Absci (NASDAQ:ABSI) Shares Gap Down After Earnings Miss - marketbeat.com
Absci (NASDAQ:ABSI) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
BTIG Research Reiterates Buy Rating for Absci (NASDAQ:ABSI) - MarketBeat
Absci (ABSI) Is Up 11.0% After Lilly Backs ABS-201 With US$40 Million Investment – Has The Bull Case Changed? - Yahoo Finance
TD Cowen Maintains Absci Corp(ABSI.US) With Buy Rating - Moomoo
ABSI SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Absci Q2 2026 Earnings Call Transcript - MarketBeat
Absci Q2 Loss Narrows, Revenue Declines - Moomoo
Why is Absci stock tumbling today? - Investing.com
ABSI Looks 934.1% Overvalued on GF Value™ - GuruFocus
Absci Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Absci misses Q2 2026 estimates as stock falls after hours - Investing.com Nigeria
Absci (NASDAQ:ABSI) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Absci Corp Stock (ABSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Absci Corp Stock (ABSI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pangalos Menelas N | Director |
May 13 '26 |
Buy |
5.36 |
37,453 |
200,748 |
232,308 |
| Busch Andreas | Chief Innovation Officer |
Mar 12 '26 |
Buy |
2.29 |
100,000 |
229,000 |
421,446 |
| Pangalos Menelas N | Director |
Feb 27 '26 |
Buy |
2.74 |
75,095 |
205,760 |
189,055 |
| McClain Sean | Chief Executive Officer |
Feb 23 '26 |
Option Exercise |
1.21 |
396,399 |
479,643 |
8,730,966 |
| McClain Sean | Chief Executive Officer |
Feb 02 '26 |
Sale |
2.99 |
26,761 |
80,015 |
8,334,567 |
| Jonasson Zachariah | CFO / CBO |
Feb 02 '26 |
Sale |
2.99 |
17,496 |
52,313 |
383,538 |
| VAN HOUTEN FRANS | Director |
Dec 05 '25 |
Buy |
3.72 |
40,000 |
148,800 |
63,320 |
| Pangalos Menelas N | Director |
Sep 22 '25 |
Buy |
2.66 |
95,785 |
254,788 |
113,960 |
| Bedrick Todd | SVP, CAO |
Sep 22 '25 |
Buy |
2.70 |
10,000 |
27,000 |
180,428 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):